Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures
- 1 January 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (1) , 399-406
- https://doi.org/10.1124/jpet.104.073965
Abstract
Recent studies indicating that some nonsteroidal anti-inflammatory drugs (NSAIDs) selectively modulate γ-secretase cleavage of amyloid precursor protein (APP) while sparing Notch processing have generated interest in discovery of novel γ-secretase modulators with the “NSAID-like” efficacy profile. The objective of the present studies was to compare the efficacy of a subset of NSAIDs with previously reported classical γ-secretase inhibitors LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]and DAPT [N-[N- (3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester] in Tg2576 mice. Flurbiprofen (10 and 25 mg/kg/day) was overtly toxic and elicited significant (but nonselective) reductions in both Aβ(1-40) and Aβ(1-42) in the plasma in one of two studies. Flurbiprofen also produced a small reduction in Aβ(1-40) in the cortex at 25 mg/kg/day but did not affect Aβ levels in hippocampus or cerebrospinal fluid. Ibuprofen and sulindac sulfide were neither overtly toxic nor efficacious at doses up to 50 mg/kg/day. The effects of NSAIDs LY-411575 and DAPT were tested in guinea pig embryonic neuronal cultures to determine whether the selective reductions in Aβ(1-42) observed in cell lines overexpressing human mutant APP can be reproduced in a neuronal model of physiological Aβ production and secretion. Flurbiprofen and sulindac nonselectively reduced Aβ(1-40) and Aβ(1-42) at concentrations ≥125 μM, although cytotoxicity was noted at ≥250 μM sulindac. Ibuprofen had no effect at concentrations up to 500 μM. In contrast, DAPT and LY-411575 potently and completely inhibited Aβ(1-40), Aβ(1-42), and Aβ(1-38) in the absence of cytotoxicity. The divergence of the present data from published reports raises the need to examine the conditions necessary to perceive selective Aβ(1-42) reduction by NSAIDs in neuronal tissue.This publication has 29 references indexed in Scilit:
- In vivo inhibition of Aβ production by memapsin 2 (β‐secretase) inhibitorsJournal of Neurochemistry, 2004
- Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)The Journal of Pharmacology and Experimental Therapeutics, 2004
- Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase InhibitorJournal of Biological Chemistry, 2003
- Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer???s DiseaseDrugs, 2003
- Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP MouseExperimental Neurology, 2002
- A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activityNature, 2001
- Cyclooxygenase‐independent actions of cyclooxygenase inhibitorsThe FASEB Journal, 2001
- Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brainJournal of Neurochemistry, 2001
- Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic MiceScience, 1996
- Optimized survival of hippocampal neurons in B27‐supplemented neurobasal™, a new serum‐free medium combinationJournal of Neuroscience Research, 1993